Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $3.0 million.

  • Prime Medicine's Change in Account Payables rose 10079.31% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 17423.69%. This contributed to the annual value of -$5.3 million for FY2024, which is 15751.64% down from last year.
  • Per Prime Medicine's latest filing, its Change in Account Payables stood at $3.0 million for Q3 2025, which was up 10079.31% from -$3.3 million recorded in Q2 2025.
  • Prime Medicine's Change in Account Payables' 5-year high stood at $5.8 million during Q3 2023, with a 5-year trough of -$5.9 million in Q1 2024.
  • Its 5-year average for Change in Account Payables is $499875.0, with a median of $1.2 million in 2022.
  • As far as peak fluctuations go, Prime Medicine's Change in Account Payables surged by 153566.08% in 2023, and later plummeted by 106666.67% in 2024.
  • Over the past 5 years, Prime Medicine's Change in Account Payables (Quarter) stood at $80000.0 in 2021, then surged by 438.75% to $431000.0 in 2022, then soared by 428.77% to $2.3 million in 2023, then grew by 7.94% to $2.5 million in 2024, then increased by 23.5% to $3.0 million in 2025.
  • Its Change in Account Payables stands at $3.0 million for Q3 2025, versus -$3.3 million for Q2 2025 and $1.9 million for Q1 2025.